DBV Technologies (DBVT) Current Deferred Revenue (2015 - 2019)
DBV Technologies (DBVT) posted Current Deferred Revenue of $6.1 million for Q2 2019, up 23.51% sequentially from $5.0 million in Q4 2018.
DBV Technologies (DBVT) Current Deferred Revenue (2015 - 2019) Analysis & Trends
DBV Technologies has reported Current Deferred Revenue for 5 years, with the latest figure at $6.1 million in Q2 2019.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $6.1 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $6.1 million (changed N/A YoY) and the FY2018 annual result came in at $5.0 million, up 58.0% from the prior year.
- Current Deferred Revenue advanced to $6.1 million in Q2 2019 per DBVT's latest filing, from $5.0 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $6.1 million in Q2 2019 and troughed at $867028.8 in Q4 2015.
- A 5-year average of $3.8 million and a median of $3.5 million in 2016 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2016 and 2017: Current Deferred Revenue jumped 304.48% in 2016, then slipped 6.36% in 2017.
- Over 5 years, Current Deferred Revenue stood at $867028.8 in 2015, then surged by 304.48% to $3.5 million in 2016, then fell by 6.36% to $3.3 million in 2017, then soared by 51.54% to $5.0 million in 2018, then grew by 23.51% to $6.1 million in 2019.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $6.1 million, $5.0 million, and $3.3 million for Q2 2019, Q4 2018, and Q4 2017 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 6.15 Mn |
| Dec 31, 2018 | 4.98 Mn |
| Dec 31, 2017 | 3.28 Mn |
| Dec 31, 2016 | 3.51 Mn |
| Dec 31, 2015 | 867,028.77 |